objective To determine whether combination therapy would improve therapeutic outcome in eumycetoma caused by Madurella mycetomatis.
Introduction
Mycetoma is a chronic granulomatous infection which can be caused by either bacteria (actinomycetoma) or fungi (eumycetoma) [1] . It is characterised by painless subcutaneous lesions, with a tumorous appearance [1] . Characteristic of this infection is that the causative agent organises itself in granules called grains [1] . Mycetoma is extremely difficult to treat because of these grains. Long treatment durations are needed for both actinomycetoma and eumycetoma [2] . For eumycetoma, medical treatment is suboptimal and not curative [2] . Hence, surgical excision is an integral treatment modality, frequently performed after 6 months of itraconazole treatment. The medical treatment with itraconazole is usually continued for another 6 months post-operatively. The aim of the pre-operative medical treatment is to enhance the formation of fibrous capsule around the lesion to facilitate surgical removal [2] . The aim of the post-operative medical treatment is to remove any residual fungal hyphae [2] . The fact that actinomycetoma is amendable to medical therapy only indicates that this might also be the case for eumycetoma with the proper drug or drug combination.
Currently, actinomycetoma is treated with a combination of antimicrobial agents consisting of trimethoprimsulfamethoxazole and an aminoglycoside [2] [3] [4] [5] [6] . The aminoglycoside differs by country; in both Mexico and Sudan, amikacin sulphate is used (Welsh regimen [2, 3] ), whereas in India, gentamicin is more common ). In general, addition of an aminoglycoside to trimethoprim-sulfamethoxazole has increased the complete cure rate from 30.8% to 42.0% and decreased the patients' non-response rate from 10.3% to 3.7% [7] . Currently, cure rates of 90% are reported for the Welsh regimen and for patients not responding to this regimen rifampicin can be added with an excellent reported cure rate of 100% (Modified Welsh regimen [8] ).
Combination of antifungal agents has been proven beneficial for the subcutaneous fungal infection chromoblastomycosis [9] . However, for eumycetoma, combination of antifungal agents is rarely used in the endemic regions. A review of the medical literature revealed only a small number of eumycetoma patients in Europe ever receiving combination therapy. In these reports, an azole was combined with either terbinafine or with caspofungin [10] ; however, these patients usually received monotherapy with an azole afterwards. Hence, it is difficult to draw a conclusion from these few reports on the benefit of combination therapy for eumycetoma.
We recently developed an in vivo model in Galleria mellonella larvae in which we are able to produce eumycetoma grains. In this model, the most common causative agent Madurella mycetomatis is injected in the hemolymph of these larvae and within 4 h black grains are formed [11] . This model can be used to study the efficacy of antifungal agents. In a previous study, we demonstrated that amphotericin B and terbinafine were able to prolong larval survival, but ketoconazole, itraconazole, voriconazole and posaconazole were not [12] . Furthermore, in a mouse model, it was also demonstrated that amphotericin B was able to prevent grain formation, but itraconazole was not [13] .
Currently, itraconazole is considered the drug of choice to treat eumycetoma [2] . Also terbinafine has been used in a small study [14] . But large cohort studies in which these drugs were combined have not been performed. The azoles and terbinafine both inhibit the ergosterol synthesis pathway, but at different points of the synthesis pathway. The azoles inhibit lanosterol 14 a-demethylase, while terbinafine inhibits squalene epoxidase [15] . Amphotericin B also has ergosterol as its target, but instead of preventing its synthesis, it binds to ergosterol and forms pores in the cell membrane [15] . As these antifungal agents all target ergosterol on a different manner, we wondered if combining different classes of antifungal agents would improve the therapeutic outcome of mycetoma. In vitro, synergy was obtained in 1 of 8 M. mycetomatis isolates tested with the combination itraconazole and terbinafine [16] , but no in vivo data are currently available. Therefore, to determine whether therapeutic outcome will be improved when drugs are combined we used our G. mellonella model of M. mycetomatis grains and treated the larvae with different combinations of antifungal agents.
Materials and Methods

Galleria mellonella larvae
Final sixth-instar G. mellonella larvae were acquired from Kreca Ento-Feed BV (Ermelo, the Netherlands) and kept at room temperature on wood shavings in the dark until use. Larvae were used within 5 days of receipt. Larvae of approximately 300-500 mg showing no discoloration were selected for the experiments.
Infection of G. mellonella larvae with M. mycetomatis and antifungal treatment Galleria mellonella larvae were infected with M. mycetomatis isolate Mm55 according to the previously published protocol [12, 17] . In short, M. mycetomatis mycelia were cultured for 2 weeks at 37°C in colourless RPMI 1640 medium supplemented with L-glutamine (0.3 g/l), 20 mM morpholinepropanesulfonic acid (MOPS) and chloramphenicol (100 mg/l; Oxoid, Basingstoke, UK). Mycelia were harvested by filtration and sonicated for 2 min at 28 micron. The resulting homogenous suspension was diluted to an inoculum size of 4 mg wet weight per larvae. Inoculation was performed by injecting 40 ll of the fungal suspension in the last left proleg with an insulin 29-G U-100 needle (BD diagnostics, Sparks, USA). To ensure that no contamination occurred during the preparation of the inoculum, 10 ll of each inoculum prepared was inoculated on Sabouraud and blood agar plates. Larvae were treated with either 1 mg/kg amphotericin B (AMB), 5.7 mg/kg itraconazole (ITZ), 7.14 mg/kg terbinafine (TBF) or combinations of these antifungal agents. These dosages were chosen to mimic the concentrations of antifungal agents in human serum. A dosage of 1 mg/kg AMB or 7.14 mg/kg terbinafine resulted in a Cmax for amphotericin B or terbinafine which were comparable to the Cmax found in human serum [12] . The Cmax/MIC is the PK/PD index determining therapeutic efficacy for amphotericin B; for terbinafine, it is not established [18] . A dosage of 5.7 mg/kg itraconazole (ITZ) resulted in 61.9% of the human AUC 24h [12] , the PK/PD index determining therapeutic efficacy [18] . Higher dosages of itraconazole could not be administered due to problems in solubility. As a control, larvae treated with 5% glucose were included. All antifungal solutions were prepared in 5% glucose solution. Each larva received three injections of antifungal agent via its prolegs. To minimise damage to the larvae, each injection was given via a different proleg. For therapeutic purposes, antifungal agents were administered 4 h, 28 h and 52 h after infection. To monitor the course of infection, larvae were checked daily for survival for 10 days. If during these 10 days larvae formed pupa, these individuals were left out of the equation, because we could not ascertain that these individual larvae would have died or survived during the infection. At day 3 and day 10 after inoculation, larvae were dissected to determine if black grains were present by macroscopic observation and histological examination. If grains were present, culture on Sabouraud agar was performed to determine their viability.
Histological examination
Larvae were injected with 100 ll of the 10% buffered formalin and transferred into 15-ml tubes containing 10 ml 10% buffered formalin. After 24-h to 48-h fixation, whole larvae were dissected longitudinally into two halves with a scalpel and fixated in 10% formalin for at least another 48 h [19] . The two halves of larvae were routinely processed for histological examination. Sections were stained with haematoxylin and eosin (HE).
Fungal burden
Five larvae from each group were sacrificed at day 3 post-infection to determine the fungal burden. Hemolymph was collected and measured at 405 nm to assess melanisation [12, 17] . To assess the number of colonyforming units (CFU) per larvae, 10 chrome steal metal balls and 1 ml PBS were added. Larvae were homogenised in a Qiagen TissueLyser for 5 min at 30 Hz [12, 17] . From each homogenised larvae, 250 ll undiluted, 50 ll undiluted and 50 ll 1:10 diluted suspensions were plated out on Sabouraud-gentamicin agar. Plates were incubated at 37°C for 2 weeks, and the number of CFUs per larvae was determined.
Statistical analysis
A log-rank test was used to compare the survival curves. To determine differences in melanisation or CFU count between the different groups, the Mann-Whitney test was performed. A P-value <0.05 was deemed significant.
Results
Combination of antifungal agents does not enhance survival
After infecting G. mellonella larvae with M. mycetomatis strain mm55, they were treated with itraconazole ( Figure 1a, b) , terbinafine (Figure 1a , c) or amphotericin B (Figure 1b, c) . Treatment started at 4 h past inoculation, a time point at which fungal grains were formed [12] . Itraconazole and terbinafine did not enhance larval survival (log rank, P = NS) ( Figure 1a) ; only 3 of 28 and 1 of 26 larvae survived, respectively. Only amphotericin B did enhance survival (log rank, P = 0.0009) ( Figure 1b) ; 8 of 27 larvae survived. As itraconazole, terbinafine and amphotericin B all belong to different classes of antifungal agents, we wondered whether combining these drugs would enhance the survival. When larvae were treated with a combination of itraconazole and terbinafine, all 29 larvae died (Figure 1a) . No significant difference was noted when this combination was compared to the 5% glucose-treated group, the itraconazole-treated group and the terbinafine-treated group (log rank, P = NS, for all combinations tested) (Figure 1a) . When larvae were treated with a combination of itraconazole and amphotericin B, no survival was noted (Figure 1b ). All 28 larvae died. This combination thus led to a significant decrease in survival vs. amphotericin B monotherapy (log rank, P = 0.0155) (Figure 1b) . When larvae were treated with a combination of amphotericin B and terbinafine, only 3 out of 29 larvae survived (Figure 1c ). This was not significantly different from the 5% glucose-treated larvae or the terbinafine-treated larvae. Compared to amphotericin B monotreatment, a significant decrease in survival was noted with this combination therapy (log rank, P = 0.0155) (Figure 1c) .
To determine whether treatment with these antifungal agents would reduce the burden of infection, the number of CFU per larvae was determined on day 3. Larvae treated with the antifungal agents had similar CFU per larvae as larvae treated with 5% glucose (Mann-Whitney, P > 0.05) (Figure 1e) . Also, melanisation of larvae did not differ between the groups (Mann-Whitney, P > 0.05) (Figure 1f ). To determine whether there were differences in grain formation itself, histopathological sections were prepared on day 3. At this time point, grains had matured and cement material was present (Figure 2c) . Also a collagen-like capsule was seen surrounding the grain. Similar pictures are seen for larvae treated with itraconazole (Figure 2a) , terbinafine (Figure 2e ) or amphotericin B (Figure 2i ) or combinations thereof (Figures 2d, g and  h) . On day 10, surviving larvae were prepared for histopathological examination. It appeared that grains were still present inside the larvae, but that they were encapsulated [17] . The encapsulation was irrespective of the class of antifungal agents used. The same phenomenon was seen for the azoles, amphotericin B and terbinafine.
Discussion
In this study, we demonstrated that combining different classes of antifungal agents did not enhance the survival of M. mycetomatis-infected G. mellonella larvae. Instead of improving the therapeutic outcome, combining either itraconazole or terbinafine with amphotericin B actually resulted in a significant lower survival of infected larvae compared to amphotericin B monotherapy.
The similarity in survival rates between glucose-treated larvae and larvae treated with either itraconazole, terbinafine, or combinations of itraconazole and terbinafine, itraconazole and amphotericin B and terbinafine and amphotericin B was confirmed by similar CFUs per larvae and similar melanisation values per larvae. Strangely, the Treatment consisted of (a) 5% glucose, 5.7 mg/kg itraconazole, 7.14 mg/kg terbinafine or a combination of 5.7 mg/kg itraconazole and 7.14 mg/kg terbinafine; (b) 5% glucose, 5.7 mg/kg itraconazole, 1 mg/kg amphotericin B or a combination of 5.7 mg/kg itraconazole and 1 mg/kg amphotericin B or (c) 5% glucose, 7.14 mg/kg terbinafine, 1 mg/kg amphotericin B or a combination of 7.14 mg/kg terbinafine and 1 mg/kg amphotericin. Compared to larvae treated with 5% glucose only, enhanced survival was only noted for amphotericin B (log rank P = 0.0009). Next to survival also some secondary parameters of therapeutic efficacy were measured. These included (d) the number of colony-forming units (CFU) per larvae and (e) melanisation of hemolymph. Based on the Mann-Whitney test, none of the antifungal treatments resulted in a reduced number of CFUs (Mann-Whitney, P > 0.05) or reduced melanisation of the larvae (MannWhitney, P > 0.05).
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enhanced survival with amphotericin B monotherapy did not result in corresponding lower CFUs per larvae or a lower melanisation value per larvae. This could be caused by interference of antifungal agents to the biosynthetic make-up of the fungal grains. A different composition of the fungal cement material could result in an easier release of fungal hyphae from the cement material during mechanical disruption, which in its turn might result in a higher number of CFU per grain. Furthermore, under influence of antifungal treatment, the grain itself might
(e) (f) (g) Figure 2 Histopathological sections of grains in Madurella mycetomatis-infected Galleria mellonella larvae, treated with different combinations for antifungal agents for 3 days and sacrificed 72 h after inoculation of M. mycetomatis. (a) larvae treated with 5% glucose, (b) larvae treated with itraconazole, (c) larvae treated with a combination of itraconazole and terbinafine, (d) larvae treated with terbinafine, (e) larvae treated with a combination of itraconazole and amphotericin B, (f) larvae treated with a combination of terbinafine and amphotericin B, (g) larvae treated with amphotericin B. Grains are clearly visible (indicated with a G). They are melanised (as seen by the brown colour), cement material is present (as seen by the brown material between the hyphae), and a capsule (indicated by arrow) is surrounding the grains. be smaller in size. If more smaller grains are found within a larvae, a relatively higher amount of CFUs will be obtained although the overall amount of fungal hyphae present in a larvae might be lower. Either less compact cement material or smaller grains could make M. mycetomatis more accessible towards the larval immune system, which could have resulted in relatively higher melanisation rates than larvae in which a high amount of fungal material is present but embedded in large grains.
But not only amphotericin B might influence the makeup of the grain, probably itraconazole and terbinafine can influence the make-up of the cement material too. Differences in the composition of fungal grains under influence of antifungal agents could have been responsible for the in vivo obtained antagonism noted. As already mentioned, one of the hallmarks of M. mycetomatis grains is their black appearance, they are highly melanised. M. mycetomatis melanin has been shown to offer protection against itraconazole [20] . In Alternaria infectoria, increased melanisation was observed in the presence of itraconazole [21] . In Sporotrix schenckii sensu stricto and Sporotrix brasiliensis, melanisation protected the fungi from dying by amphotericin B [22] . In Paracoccidioides brasiliensis, the susceptibility of melanised cells to both itraconazole and amphotericin B was drastically reduced [23] . Due to alterations in the absorbance spectra of the drugs in the presence of melanin, this reduction was believed to be the result of binding of itraconazole and amphotericin B to the free carboxyl groups present in melanin [23] . This binding would prevent the binding of the drug to its target. Thus, if a grain was exposed to itraconazole, it might have become more heavily melanised, which could have protected M. mycetomatis from killing by amphotericin B. But melanin is not the only component present in the cement material. The cement material within the fungal grain resembles the extracellular matrix present in fungal biofilms. Both biofilms and grains are highly resistant to antifungal agents [24] [25] [26] . In the case of Aspergillus fumigatus biofilms, it was recently demonstrated that prior exposure of voriconazole made the biofilms more resistant to amphotericin B treatment [25] . Voriconazole exposure resulted in increased production of the extracellular matrix, which directly impacts amphotericin B with the sterols [25] . Inhibition of the stress protein heat-shock protein 90 (hsp90) or extracellular DNA (eDNA), both important in the adaptive resistance mechanisms in A. fumigatus biofilms and implicated in the increased production of extracellular matrix, reverted this resistant phenotype [25] . Ultrastructurally, this could also be the case in M. mycetomatis grains. Thus, if in the M. mycetomatis grain similar processes play a role, exposure to itraconazole or terbinafine could have resulted in increased production of the extracellular matrix and an increased melanisation of this matrix. This would then bind amphotericin B preventing it to reach its target ergosterol. Furthermore, the ergosterol target itself is also reduced by the activity of itraconazole and terbinafine, which makes the fungus even more resistant to amphotericin B [27] . This together could then result in the antagonistic reaction noted when treating G. mellonella larvae with a combination of itraconazole and amphotericin B or terbinafine and amphotericin B.
Whether this antagonistic action will persist in a clinical situation needs to be seen. So far, we only found one mycetoma patient in the literature who was treated with a combination of amphotericin B and itraconazole [28] . He received itraconazole combined with intralesional injections of amphotericin b and greatly improved [28] . Furthermore, in animal models for other fungal infections, indifference to synergy has been observed when amphotericin B was combined with an azole [27, [29] [30] [31] [32] [33] or with terbinafine [34, 35] . Clearly more in vivo studies in different animal models and more clinical data are needed to determine whether combining itraconazole and amphotericin B will be beneficial for mycetoma patients.
